Fig. 2.

Current therapeutic strategies of COVID-19. In the early stages of COVID-19 and in non-hospitalized patients there is no evidence to support the use of any antiviral or immunomodulatory agent, except for SARS-mAbs in selected subgroups of patients. In hospitalized patients requiring supplemental oxygen, non-invasive or mechanical ventilation the use of remdesivir in combination with dexamethasone, with or without the use of IL-6 or JAK inhibitors are considered. The National Institute of Allergy and Infectious Diseases (NIAID), Ordinal scale: 1= Not hospitalized, no limitations on activities; 2= Not hospitalized, limitations on activities or, receiving home oxygen, or both; 3= Hospitalized, no supplemental oxygen, no ongoing medical care; 4= Hospitalized, no supplemental oxygen but should receive ongoing medical care; 5= Hospitalized, receiving supplemental oxygen through low-flow devices; 6= Hospitalized, receiving oxygen through non-invasive ventilation or high-flow oxygen devices; 7= Hospitalized, invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO).